Dr. Mahavir Chougule

Associate Professor of Pharmaceutical Sciences

Dr. Mahavir ChouguleEducation

Dr. Chougule’s C.V.


  • PHA 527 Biotechnology
  • PHA 548 Project Development
  • PHA 549 Introduction to Research
  • PHA 742 Foundations in Pharmaceutical Sciences
  • PHA 743 Foundations in Research
  • PHA 807 Pharmaceutical Biotechnology

Research Interests

Dr. Chougule’s research focuses on the investigation of co-delivery of the therapeutic agent siRNA, proteins using targeted nanoparticles for the treatment of lung cancer, asthma, COVID-19 and breast cancer. His lab applies interdisciplinary strategies to improve understanding of drugs or nanocarriers’ therapeutic effects. His group is designing a new generation of nanoparticles that could recognize the location of disease cells and selectively deliver drugs and genes to exert therapeutic effects while sparing normal healthy tissues. Ongoing projects include:

  • Targeted inhalation delivery of drugs and siRNA using bio-engineered polymeric or lipidic nanoparticles for the treatment of lung cancer and asthma
  • Multi-target-based combination therapies via natural and bioengineered polymeric systems
  • Tumor-responsive natural and bio-engineered material-based nanocarrier
  • Delivery of Immunomodulatory agents for COVID-19

Chougule Laboratory Website

Teaching Philosophy

My teaching philosophy is to provide student-centered active learning, creative thinking, problem-solving and lifelong interdisciplinary learning skills. The goal of my teaching is to explore many possible ways to mentor pharmacy students, as they become self-directed learners promoting patient-centered health care. My philosophy involves fostering an enjoyable and supportive environment for students learning, conducive to learning skills that will be useful throughout their lifetime. Every student is unique and has his or her own style of learning. I have, therefore, intentionally included a variety of different styles of presenting course material to accommodate students with differing comprehension abilities. I am committed to encouraging lifelong learning for my students and myself. I enjoy interacting with and conveying my passion, knowledge and experience to my pharmacy students.

Awards and Honors

  • The Koichi and Taniyo Taniguchi Award for Excellence and Innovation, 2016
  • 2015 AACR Minority-Serving Institution Faculty Scholar in Cancer Research Award
  • Postdoctoral Research Fellow award, Florida Department of Health, 2010

Selected Patents

  • WO/2008/026044 and WO/2008/129465

Selected Publications

  • PubMed
  • Vinjamuri BP, Papachrisanthou K, Haware RV, Chougule MB*, Gelatin solution pH and incubation time influences the size of the nanoparticles engineered by desolvation. Journal of Drug Delivery Science and Technology 2021, 63, 02423
  • Shadambikar, Marathe S, Ji Nan , Bandari S, Chougule MB, Repka M*. Formulation Development of Itraconazole Loaded PEGylated Nano-Lipid Carriers for Pulmonary Aspergillosis Using Hot Melt Extrusion Technology, International Journal of Pharmaceutics, 2021, Volume 3, December 2021, 100074
  • Chandrasiri I, Abebe DG, Yaddehige ML, Dal Williams JS, Zia MF, Dorris A, Barker A, Vinjamuri, BP, Le N, Gayton JN, Chougule MB, Hammer NI, Flynt A, Delcamp JH, Watkins D Self-Assembling PCL-PAMAM Linear Dendritic Block Copolymers (LDBCs) for Bioimaging and Phototherapeutic Applications. ACS Applied Bio Materials, 2021, 3(9), 5664-5677
  • Yang R, Nam K, Kim SW, Turkson J, Zou Y, Zuo YY, Haware RV, Chougule MB*, Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers. Mol Pharm. 2017 Jan 3;14(1):252-263.
  • España-Serrano L and Chougule MB*. Enhanced anticancer activity of PF-04691502, a dual PI3K/mTOR inhibitor, in combination with VEGF siRNA against non-small cell lung cancer. Molecular Therapy – Nucleic Acids (Nature publishing group), 2016 Nov 15;5(11):e384.
  • Andey T, Patel A, Marepally S, Chougule M, Spencer S, Rishi AK, Singh M, Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS One.2016 Jan 12;11(1):e0146804.
  • Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated Delivery of siRNA/miRNA in Combination with Chemotherapeutic Agents for Cancer Therapy: Current Progress and Advances. Journal of controlled release. 2014; 194C:238-256.
  • Patel, A. R., B. Chougule, E. Lim, K. P. Francis, S. Safe, and M. Singh, Theranostic tumor homing NCs for the treatment of lung cancer. Nanomedicine, 2014. 10(5):1053-63.
  • Youngren SR, Tekade RK, Gustilo B,  Hoffmann PR, Chougule MB*, STAT-6 siRNA Encapsulated Nanocarriers: Formulation, Characterization, and Ex-vivo Proof of Concept using an Adenocarcinomic Cell Line, BioMed research international, 2013;2013:858946.
  • Patel AR, Chougule MB*, Ian T, Patlolla RR, Guangdi W, Singh M*. Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in combination with Docetaxel, Pharmaceutical research. 2013, 30(5):1435-46.
  • Youngren SR, Mulik R, Jun B, Hoffmann PR, Morris KR, Chougule MB*, Susanne R. Youngren, Preparation and characterization of a selenium-loaded nanoliposomal formulation, 2013, AAPS PharmSciTech, 2013 Sep;14(3):1012-24.
  • Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and In Vitro-In Vivo Correlation (IVIVC) of novel methylene-substituted 3,3′ diindolylmethane (DIM), European journal of pharmaceutical sciences. 2012; 12;46(1-2):8-16.
  • Chougule MB, Patel AR, Sachdeva P, Jackson T, Singh M. Anti-cancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. Lung Cancer, 2011, 71(3):271-82.
  • Ichite N, Chougule M, Jackson T, Fulzele S, Safe S, and Singh M, Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer, Clinical cancer research. 2009; 15:543-552.


Contact Dr. Chougule

Moye Pharmacy and Health Sciences Center #278
(678) 547-6748